

# Transcriptome and isoform reconstruction with long reads

Adam Ameur, PhD  
NGI, Uppsala Genome Center  
[adam.ameur@igp.uu.se](mailto:adam.ameur@igp.uu.se)  
Enabler for Life Sciences

# National Genomics Infrastructure



**NGI staff:** 60 -70 FTE, including head of facility, lab research engineers, bioinformaticians, IT-experts, project coordinators.

**UPPMAX/UPPNEX:** Uppsala multidisciplinary center for advanced computational science, UPPNEX: UPPmax NEXt generation sequencing Cluster & Storage.

Enabler for Life Sciences

# DNA sequencing at all scales



One of the most well-equipped NGS sites in Europe!

- 10 Illumina HiSeq Xten
- 17 Illumina HiSeq 2000/2500
- 3 Illumina MiSeq
- 1 Illumina NextSeq
- 2 Life Technologies Ion Torrent
- 6 Life Technologies Ion Proton
- 2 Pacific Biosciences RSII
- 2 Sanger ABI3730
- 1 Argus Whole Genome Map. Syst.
- 1 Oxford Nanopore Minion


Enabler for Life Sciences

# RNA-sequencing

## with short reads

Enabler for Life Sciences

# RNA-seq: standard procedure




# RNA-seq: the main question

What to do with this?




Enabler for Life Sciences




# RNA-seq: analysis




# Complicating factor: alternative splicing



# RNA-seq: problem with short reads



# RNA-seq: problem with short reads



Enabler for Life Sciences

# RNA-sequencing

# with very long reads!!!

Enabler for Life Sciences


# Pacific Biosciences RS II

- Pacific Biosciences
  - Single molecule sequencing
  - Very long read lengths (up to 30 kb)
  - Rapid sequencing
  - Can detect base modifications (e.g. methylation)
  - Relatively low throughput

Pacific Biosciences RSII



# PacBio – Sequencing Template




## Polymerase Read

### Definition:

- Sequence of nucleotides incorporated by polymerase while reading a template
- Includes adapters
- Often called “read”
- Includes adapters
- 1 molecule, 1 pol. read

### Uses:

- QC of instrument run
- Benchmarking



## Subread

### Definition:

- Single pass of template
- Adapters removed
- 1 molecule,  $\geq 1$  subread

### Unique data:

- Kinetic measurements
- Rich QVs

### Uses:

- Applications



## Read (of Insert)

### Definition:

- Represents highest-quality single-sequence for an insert, regardless of number of passes
- Generalizes CCS for  $< 2$  passes & RQ  $< 0.9$
- 1 or more passes
- 1 molecule, 1 read

### Uses:

- Library QC
- Applications

# PacBio output

- PacBio throughput
  - ~ 500Mb-1Gb/SMRT cell

~1 bacterial genome

~1 bacterial transcriptome


1 human genome = 150 SMRT cells



- PacBio read lengths: 500bp-30kb

# PacBio – Current read lengths

- >10kb average read lengths! (run from April 2014)



# Iso-Seq: Full length RNA-seq on PacBio!


- Single molecule sequencing
  - One read – one transcript
- Transcript in full length
  - No assembly required
- No systematic bias
  - CG-rich, AT-rich, tandem repeats

# RNA-sequencing on PacBio


On average, 8 alt. isoforms per gene in human




Candidate space:  
 $5.8 \times 10^{76}$



# PacBio Iso-Seq - library preparation



# PacBio Iso-Seq – reads of insert




Full-Length = 5' primer seen, polyA tail seen, 3' primer seen

- Identify and remove primers and polyA/T tail
  - Identify read strandedness

# PacBio Iso-Seq: ROI of 1kb lib (2 cells)

Read Bases of Insert	78,108,189
Mean Read Length of Insert	1,687
Mean Number of Passes	8.0
Number of full-length non-chimeric reads	<b>35,467</b>
Average full-length non-chimeric read length	1,679

Read Length Of Insert



# PacBio Iso-Seq: examples



GeneCards Summary for TMEM25 Gene:

**TMEM25** is a protein-coding gene. Diseases associated with TMEM25 include breast cancer.

# PacBio Iso-Seq: examples (from PacBio)

Tissue	Size Selection	FL Reads	Average FL Readlength	Number of Unique FL Transcripts	Number of Gene Loci	Max Transcript Length
Brain	1 - 2 kb	159792	1785	10289	6356	8823
	2 - 3 kb	165942	2794			
	3 - 6 kb	118568	4104			
	5 - 10 kb	59607	6490			
Heart	1 - 2 kb	134462	1629	6896	4352	8528
	2 - 3 kb	89472	2910			
	3 - 6 kb	126927	4027			
	5 - 10 kb	43486	6323			
Liver	1 - 2 kb	197772	1725	6124	3497	4754
	2 - 3 kb	157531	2605			
	3 - 6 kb	130438	3876			


<http://blog.pacificbiosciences.com/2014/10/data-release-whole-human-transcriptome.html>

# PacBio Iso-Seq: examples (from PacBio)

Tissue	Size Selection	FL Reads	Average FL Readlength	Number of Unique FL Transcripts	Number of Gene Loci	Max Transcript Length
Brain	1 - 2 kb	159792	1785	10289	6356	8823
	2 - 3 kb	165942	2794			
	3 - 6 kb	118568	4104			
	5 - 10 kb	59607	6490			
Heart	1 - 2 kb	134462	1629	6896	4352	8528
	2 - 3 kb	89472	2910			
	3 - 6 kb	126927	4027			
	5 - 10 kb	43486	6323			
Liver	1 - 2 kb	197772	1725	6124	3497	4754
	2 - 3 kb	157531	2605			
	3 - 6 kb	130438	3876			

<http://blog.pacificbiosciences.com/2014/10/data-release-whole-human-transcriptome.html>

# PacBio Iso-Seq: examples (from PacBio)



<http://blog.pacificbiosciences.com/2014/10/data-release-whole-human-transcriptome.html>


# PacBio Iso-Seq: experimental design

So how many SMRT cells do I need?

Approximate scope guidance:

- **1 SMRT Cell:** targeted, gene-specific isoform characterization
- **1-8 SMRT Cells:** get a high-level overview of the transcriptome and isoforms of abundant transcripts
- **8-50 SMRT Cells:** get a detailed look at most transcripts and their isoforms
- **>50 SMRT Cells:** get a very thorough look at transcriptome with rare transcripts and rare isoforms or intermediates

! Depends strongly on transcriptome complexity of the organism being studied !




# Targeted RNA-sequencing with very long reads!!!

Enabler for Life Sciences

# Clinical project: Chronic Myeloid Leukemia

- BCR-ABL1 fusion protein – a CML drug target

The BCR-ABL1 fusion protein can acquire resistance mutations following drug treatment



[www.cambridgemedicine.org/article/doi/10.7244/cmj-1355057881](http://www.cambridgemedicine.org/article/doi/10.7244/cmj-1355057881)

# BCR-ABL1 workflow – PacBio Sequencing

Cavelier et al. BMC Cancer (2015) 15:45  
DOI 10.1186/s12885-015-1046-y



RESEARCH ARTICLE

Open Access

## Clonal distribution of *BCR-ABL1* mutations and splice isoforms by single-molecule long-read RNA sequencing

Lucia Cavelier<sup>1†</sup>, Adam Ameur<sup>1†</sup>, Susana Häggqvist<sup>1</sup>, Ida Höijer<sup>1</sup>, Nicola Cahill<sup>1</sup>, Ulla Olsson-Strömberg<sup>2</sup> and Monica Hermanson<sup>1</sup>


### Abstract

**Background:** The evolution of mutations in the *BCR-ABL1* fusion gene transcript renders CML patients resistant to tyrosine kinase inhibitor (TKI) based therapy. Thus screening for *BCR-ABL1* mutations is recommended particularly in patients experiencing poor response to treatment. Herein we describe a novel approach for the detection and surveillance of *BCR-ABL1* mutations in CML patients.

**Methods:** To detect mutations in the *BCR-ABL1* transcript we developed an assay based on the Pacific Biosciences (PacBio) sequencing technology, which allows for single-molecule long-read sequencing of *BCR-ABL1* fusion transcript molecules. Samples from six patients with poor response to therapy were analyzed both at diagnosis and follow-up. cDNA was generated from total RNA and a 1.6 kb fragment encompassing the *BCR-ABL1* transcript was amplified using long range PCR. To estimate the sensitivity of the assay, a serial dilution experiment was performed.

**Results:** Over 10,000 full-length *BCR-ABL1* sequences were obtained for all samples studied. Through the serial dilution analysis, mutations in CML patient samples could be detected down to a level of at least 1%. Notably, the assay was determined to be sufficiently sensitive even in patients harboring a low abundance of *BCR-ABL1* levels. The PacBio sequencing successfully identified all mutations seen by standard methods. Importantly, we identified several mutations that escaped detection by the clinical routine analysis. Resistance mutations were found in all but one of the patients. Due to the long reads afforded by PacBio sequencing, compound mutations present in the same molecule were readily distinguished from independent alterations arising in different molecules. Moreover, several transcript isoforms of the *BCR-ABL1* transcript were identified in two of the CML patients. Finally, our assay allowed for a quick turn around time allowing samples to be reported upon within 2 days.

**Conclusions:** In summary the PacBio sequencing assay can be applied to detect *BCR-ABL1* resistance mutations in both diagnostic and follow-up CML patient samples using a simple protocol applicable to routine diagnosis. The method besides its sensitivity, gives a complete view of the clonal distribution of mutations, which is of importance when making therapy decisions.




# BCR-ABL1 mutations at diagnosis

PacBio sequencing generates ~10 000X coverage!


BCR

ABL1



Sample from time of diagnosis:

# BCR-ABL1 mutations in follow-up sample




Sample 6 months later


Mutations acquired in fusion transcript.  
Might require treatment with alternative drug.

# BCR-ABL1 dilution series results


- Mutations down to 1% detected!



# Summary of mutations in 5 CML patients



# Mutations mapped to protein structure



# BCR-ABL1 - Compound mutations

P1 61m

T315I

91.8%

F359C

4.2%

3.9%

P1 68.5m

T315I

93.7%

D276G

2.0%

F359C



2.0%

H396R


1.1%

1.1%

# BCR-ABL1 - Multiple isoforms in one individual!




# BCR-ABL1 – Isoforms and protein structure




# Future bioinformatics challenge

- How to find mutations within isoforms???




# Conclusions and next steps

- Sensitive method for *BCR-ABL1* analysis!
  - Also for compound mutations and isoforms
- Method now used in clinical routine!
  - Patient samples coming to the clinic over a few months
  - Response time limit: 2 weeks



# Our clinical diagnostics pipeline!



## Step1. Create CCS reads

SMRT® Portal Home Admin Help About


**DESIGN JOB**

Job Name  Comments

Protocol  Reference


SMRT Cells Available (Viewing 1 - 50 of 62 )

SMRT Cell ID	Sample	V	User	Groups	Started	Uri
10057986255000000182308820	pb_2	v2	all		2013-10-10T09:45:16+0	/hor
10057986255000000182308820	pb_2	v2	all		2013-10-10T09:45:16+0	/hor
10057986255000000182308820	pb_2	v2	all		2013-10-10T09:45:16+0	/hor
10057986255000000182308820	pb_2	v2	all		2013-10-09T16:37:34+0	/hor
10057986255000000182308820	pb_4	v2	all		2013-10-09T16:37:34+0	/hor
10057986255000000182308820	pb_4	v2	all		2013-10-09T16:37:34+0	/hor
10057986255000000182308820	pb_3-2	v2	all		2013-10-09T16:37:34+0	/hor
10057986255000000182308820	pb_3-1	v2	all		2013-09-08T16:37:34+0	/hor
10057973255000000182308820	pb_1-8	v2	all		2013-09-12T13:25:48+0	/hor
10057973255000000182308820	pb_1-7	v2	all		2013-09-12T13:25:48+0	/hor
10057973255000000182308820	pb_1-6	v2	all		2013-09-12T13:25:48+0	/hor
10057973255000000182308820	pb_1-5	v2	all		2013-09-12T13:25:48+0	/hor



## Step2. Run mutation analysis

Details	Sample ID	Run ID	Unresolved (count)	Unknown (count)	E009E	M244V	Y283H	E285K	D276G	T318I	F389C	F389W	F399I	L384M	L387M	H396R	Date
	R3740	pb_003_1															2015-02-17
(4)	R7394	pb_003_2															2015-02-17
(4)	R7860	pb_014_3							1.8	99.8	4.6						2015-02-17
(4)	R9171	pb_014_4															2015-02-17
(5)	R8484	pb_014_5								14.3		85%					2015-02-17
(4)	R4419	pb_015_1															2015-02-17
(7)	R4765	pb_015_2															2015-02-17
(4)	R7715	pb_015_3															2015-02-17
(8)	R0452	pb_015_4															2015-02-17
(10)	R5208	pb_033_1															2015-02-17
(11)	R5616	pb_033_2															2015-02-17
(12)	R8236	pb_033_3															2015-02-17
(13)	R8333	pb_033_4															2015-02-17
(14)	R8817	pb_033_5															2015-02-17
(15)	R8885	pb_033_6								1.6		99.7%	3.1				2015-02-17
(16)	R0450	pb_033_7								2.4							2015-02-17
(17)	R10090	pb_033_8															2015-02-17
(18)	R9171	pb_033_9															2015-02-17
(19)	R5934	pb_033_10															2015-02-17
(20)	R9223	pb_099_1															2015-02-17



## Step3. Upload to result server

# News and future directions (1)



**Sequel - New PacBio instrument with higher throughput!**



**7x more data per SMRT cell!**

# News and future directions (2)

## Nanopore technology - for direct RNA sequencing?



Enables detection of modified RNA bases??